keyword
MENU ▼
Read by QxMD icon Read
search

Mronj

keyword
https://www.readbyqxmd.com/read/27856150/comparison-of-auto-fluorescence-and-tetracycline-fluorescence-for-guided-bone-surgery-of-medication-related-osteonecrosis-of-the-jaw-a-randomized-controlled-feasibility-study
#1
O Ristow, S Otto, C Geiß, V Kehl, M Berger, M Troeltzsch, S Koerdt, B Hohlweg-Majert, C Freudlsperger, C Pautke
Recent studies have indicated that bone shows auto-fluorescence under an appropriate fluorescence lamp. The aim of this preliminary study was to compare the success rates of the established tetracycline fluorescence-guided bone surgery with auto-fluorescence-guided bone surgery in the treatment of medication-related osteonecrosis of the jaw (MRONJ). Forty patients suffering from MRONJ were referred for surgical treatment and were divided randomly into two groups: auto-fluorescence (n=20) or tetracycline fluorescence (n=20) guided bone surgery...
November 14, 2016: International Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/27843453/medication-related-osteonecrosis-of-the-jaws-considerations-on-a-new-antiresorptive-therapy-denosumab-and-treatment-outcome-after-a-13-year-experience
#2
Gianfranco Favia, Angela Tempesta, Luisa Limongelli, Vito Crincoli, Eugenio Maiorano
Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication in patients receiving antiresorptive therapies for bone neoplastic localizations and osteoporosis. The aim of this study was to evaluate the clinicopathological features of MRONJ in a cohort of patients treated by new antiresorptive drugs (denosumab) and the corresponding outcome after 13-year maximum follow-up. Overall, 244 patients affected by MRONJ were treated from 2003 to 2015. After clinical and radiological examinations, all lesions were staged according to a dimensional staging system and then surgically treated...
2016: International Journal of Dentistry
https://www.readbyqxmd.com/read/27837344/platelet-rich-fibrin-may-reduce-the-risk-of-delayed-recovery-in-tooth-extracted-patients-undergoing-oral-bisphosphonate-therapy-a-trial-study
#3
Takuya Asaka, Noritaka Ohga, Yutaka Yamazaki, Jun Sato, Chiharu Satoh, Yoshimasa Kitagawa
OBJECTIVES: The aim of the present study was to evaluate the effectiveness of platelet-rich fibrin (PRF) as a wound-healing accelerator in patients undergoing oral bisphosphonate therapy and requiring tooth extractions. MATERIALS AND METHODS: A total of 102 patients were divided into a PRF group and control group. The patients received oral bisphosphonate therapy for osteoporosis for an average of 32 months. Blood was collected and PRF was introduced into the socket of the PRF group only...
November 11, 2016: Clinical Oral Investigations
https://www.readbyqxmd.com/read/27836551/clinical-features-of-peri-implant-medication-related-osteonecrosis-of-the-jaw-is-there-an-association-to-peri-implantitis
#4
Matthias Troeltzsch, David Cagna, Philip Stähler, Florian Probst, Gabriele Kaeppler, Markus Troeltzsch, Michael Ehrenfeld, Sven Otto
The purpose of this study was to examine the behavior of dental implants in patients diagnosed with MRONJ and to analyze the characteristics of peri-implant MRONJ. It was hypothesized that peri-implant parameters are not associated with peri-implant MRONJ. A retrospective study design was selected to address the research purpose. Patients with confirmed MRONJ and the simultaneous presence of dental implants who presented between 2010 and 2016 served as the study cohort. Predefined inclusion and exclusion criteria were applied...
October 6, 2016: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/27796573/secretomes-from-mesenchymal-stem-cells-participate-in-the-regulation-of-osteoclastogenesis-in-vitro
#5
Kenichi Ogata, Wataru Katagiri, Hideharu Hibi
OBJECTIVES: The receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors are novel clinically effective agents that inhibit osteoclast differentiation, function, and survival by binding to RANKL. Medication-related osteonecrosis of the jaw (MRONJ), caused as a result of treatment using denosumab, is a newly emerging type of bone necrosis, the exact pathogenesis of which is unknown. Several studies recently showed that the intravenous administration of mesenchymal stem cells (MSCs) improved the osteonecrosis of the jaw, and it was hypothesized that paracrine effects by secretomes from MSCs are the main constituent...
October 29, 2016: Clinical Oral Investigations
https://www.readbyqxmd.com/read/27780611/experimental-model-of-osteonecrosis-of-the-jaw-in-rats-treated-with-zoledronic-acid
#6
M E Kolpakova, A A Zubarevа, T D Artamonova, E K Lisovskaya, S G Chefu, O D Yagmurov, A I Yaremenko, T D Vlasov
We have examined the development of medication-related osteonecrosis of the jaws (MRONJ) in rats with no previous accumulation of zoledronic acid in the mandible. Ten male Wistar rats (weight 350-400g) were anaesthetised with chloral hydrate 450mg/kg intraperitoneally and the first and second mandibular molars on the left side were extracted. The five experimental rats were given six injections of zoledronic acid 0.18mg/kg over the next four weeks (total dose 1.08mg/kg). Two injections were given at once as an intravenous bolus injection (0...
October 22, 2016: British Journal of Oral & Maxillofacial Surgery
https://www.readbyqxmd.com/read/27771829/a-retrospective-study-of-osteomyelitis-and-osteonecrosis-of-the-jaws-and-its-etiologic-implication-of-bisphosphonate-in-asians
#7
Sung Ok Hong, Chae-Yoon Lee, Junho Jung, Deog-Yoon Kim, Christian Walter, Yong-Dae Kwon
OBJECTIVE: The objective of this study were to find the annual case trend of inflammatory jawbone diseases and to investigate the impact of medication-related osteonecrosis of the jaws (MRONJ). MATERIAL AND METHODS: A retrospective study of 372 patients diagnosed with inflammatory jawbone condition except for alveolar osteitis from 2007 to 2015 was initiated. History taking and investigation of etiologic factors MRONJ, osteoradionecrosis (ORN), odontogenic infection, foreign body, and trauma were investigated...
October 22, 2016: Clinical Oral Investigations
https://www.readbyqxmd.com/read/27771152/grade-of-sclerosis-in-the-contralateral-mandibular-area-in-osteonecrosis-of-the-jaws
#8
L Bagan, M Leopoldo-Rodado, R Poveda-Roda, J Murillo-Cortes, J M Diaz-Fernández, J Bagan
The objective of this study was to compare the grade of radiographic sclerosis between the area of osteonecrosis and the at-risk contralateral mandibular area without osteonecrosis. Three groups were studied: group 1 comprised 30 cases of medication-related osteonecrosis of the jaws (MRONJ); group 2 was the healthy contralateral area without osteonecrosis of the group 1 cases; group 3 comprised 30 healthy controls. ImageJ software was used to analyze the computed tomography images, and the grade of bone sclerosis was compared between the three groups...
October 19, 2016: International Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/27741546/bisphosphonate-and-medication-related-osteonecrosis-of-the-jaw-a-review
#9
Thomas Mücke, Christian R Krestan, David A Mitchell, Jan S Kirschke, Arno Wutzl
For patients with malignant disease taking bisphosphonates and denosumab, the incidence of medication-related osteonecrosis of the jaw (MRONJ) is up to 15% in contrast to 0.01% in patients with osteoporosis. Clinical presentation of MRONJ extends from asymptomatic exposure of bone in 94% of patients to severe cases of mandibular fractures in a minority of 4.5%. The strongest risk factors for MRONJ are invasive dental procedures and dental infections. Advances in imaging provide more preoperation information compared with panoramic radiograph...
July 2016: Seminars in Musculoskeletal Radiology
https://www.readbyqxmd.com/read/27721837/medication-related-osteonecrosis-of-the-jaw-new-insights-into-molecular-mechanisms-and-cellular-therapeutic-approaches
#10
Thomas Lombard, Virginie Neirinckx, Bernard Rogister, Yves Gilon, Sabine Wislet
In recent years, medication-related osteonecrosis of the jaw (MRONJ) became an arising disease due to the important antiresorptive drug prescriptions to treat oncologic and osteoporotic patients, as well as the use of new antiangiogenic drugs such as VEGF antagonist. So far, MRONJ physiopathogenesis still remains unclear. Aiming to better understand MRONJ physiopathology, the first objective of this review would be to highlight major molecular mechanisms that are known to be involved in bone formation and remodeling...
2016: Stem Cells International
https://www.readbyqxmd.com/read/27720716/possible-pathogenic-engagement-of-soluble-semaphorin-4d-produced-by-%C3%AE-%C3%AE-t-cells-in-medication-related-osteonecrosis-of-the-jaw-mronj
#11
Alexandru Movila, Hani Mawardi, Kazuaki Nishimura, Tomomi Kiyama, Kenji Egashira, Jae-Young Kim, Alessandro Villa, Hajime Sasaki, Sook-Bin Woo, Toshihisa Kawai
Prior consensus held that medication-related osteonecrosis of the jaw (MRONJ) lesion was composed of necrotic bone; however, more recent studies have identified inflammatory infiltrates in the lesion. Herein, we report that remarkably elevated infiltrating γδT cells (90% of lymphocytes) express Semaphorin 4D (Sema4D) in human patient with MRONJ lesion, whereas γδT cells only account for 2-5% of lymphocytes in blood. Importantly, Sema4D is implicated in the pathogenesis of T cell-mediated inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis...
October 5, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27668100/medication-related-osteonecrosis-of-jaws-a-low-level-laser-therapy-and-antimicrobial-photodynamic-therapy-case-approach
#12
Mariana Comparotto Minamisako, Guilherme Henrique Ribeiro, Mariáh Luz Lisboa, Mabel Mariela Rodríguez Cordeiro, Liliane Janete Grando
Medication-related osteonecrosis of the jaws (MRONJ) can be considered an inability of the alveolar bone to respond to an injury, which frequently leads to severe local and systemic complications. Once the problem is installed, dentist must use all therapeutic approaches recommended. This manuscript reports a successful management of MRONJ handled with antibiotics, conservative debridement, low-level laser therapy (LLLT), and photodynamic therapy (PDT) up to 12 months. As healing of MRONJ may be very slow, combined therapeutic approaches are required...
2016: Case Reports in Dentistry
https://www.readbyqxmd.com/read/27659614/pharmaceuticals-mronj-and-prostheses
#13
H Crane, V Toedtling
No abstract text is available yet for this article.
September 23, 2016: British Dental Journal
https://www.readbyqxmd.com/read/27651287/pentoxifylline-and-tocopherol-in-the-management-of-cancer-patients-with-medication-related-osteonecrosis-of-the-jaw-an-observational-retrospective-study-of-initial-case-series
#14
Adepitan A Owosho, Cherry L Estilo, Joseph M Huryn, SaeHee K Yom
OBJECTIVE: Very few studies have evaluated the efficacy of pentoxifylline and tocopherol (PENT-E) in the management of medication-related osteonecrosis of the jaw (MRONJ), although some studies have shown the therapeutic and prophylactic benefit of PENT-E in the management of osteoradionecrosis. We report the outcomes of MRONJ managed with PENT-E in patients with metastatic bone disease or multiple myeloma. STUDY DESIGN: Seven patients diagnosed with established cases of refractory MRONJ caused by antiresorptive medications for the management of metastatic bone tumors or multiple myeloma were administered PENT-E for a mean period of 16...
October 2016: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/27591091/evaluation-of-surgical-outcome-and-influencing-risk-factors-in-patients-with-medication-related-osteonecrosis-of-the-jaws
#15
Christoph Klingelhöffer, Florian Zeman, Johannes Meier, Torsten Eugen Reichert, Tobias Ettl
PURPOSE: Surgical treatment of the medication-related osteonecrosis of the jaw (MRONJ) is still challenging. We examined the outcome of the resection of osteonecrotic lesions and the influence of potential risk factors on the operative success. METHODS: Seventy six surgical interventions on 40 patients were evaluated in a prospective design with a mean follow-up of 55 weeks. Primary endpoints were: (i) maintenance of the mucosal closure and (ii) decrease of MRONJ stage...
August 9, 2016: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/27569557/osteonecrosis-of-the-jaw-in-the-absence-of-antiresorptive-or-antiangiogenic-exposure-a-series-of-6-cases
#16
Tara L Aghaloo, Sotirios Tetradis
Medication-related osteonecrosis of the jaws (MRONJ) is a well-described complication of antiresorptive and antiangiogenic medications. Although osteonecrosis can be associated with other inciting events and medications, such as trauma, infection, steroids, chemotherapy, and coagulation disorders, these are rarely reported in the literature. With the continued development and clinical use of new biologic medications for diseases such as cancer and rheumatoid arthritis, it is important to continue to evaluate their effects on the oral cavity...
July 30, 2016: Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/27544397/computed-tomographic-assessment-of-early-changes-of-the-mandible-in-bisphosphonate-treated-patients
#17
Tohru Taniguchi, Yoshiko Ariji, Michihito Nozawa, Munetaka Naitoh, Yuichiro Kuroiwa, Kenichi Kurita, Eiichiro Ariji
OBJECTIVES: To compare the computed tomography (CT) features of mandibular cancellous and cortical bones between patients with bisphosphonate (BP) administration and those without and to assess the early changes of the mandible in BP-treated patients. STUDY DESIGN: Twenty-four BP-treated patients suffering from medication-related osteonecrosis of the jaw (MRONJ) were enrolled in this study. For comparison, 20 patients suffering from osteomyelitis and 20 patients without pathology in the jaw were also enrolled, all of whom did not receive BP treatment...
September 2016: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/27530150/the-association-of-medication-related-osteonecrosis-of-the-jaw-with-actinomyces-spp-infection
#18
Guenter Russmueller, Rudolf Seemann, Kathrin Weiss, Victoria Stadler, Manuel Speiss, Christos Perisanidis, Thorsten Fuereder, Birgit Willinger, Irene Sulzbacher, Christoph Steininger
Medication-related osteonecrosis of the jaw (MRONJ) represents a complication of bisphosphonate treatment that responds poorly to standard treatment. In a retrospective cohort study we investigated a possible role of Actinomyces spp. in the pathogenesis of MRONJ. Deep biopsies of necrotic bone were collected during surgical treatment of MRONJ and evaluated by histology and microbiology for the presence of Actinomyces spp. Microbiological, demographic and clinicpathological data were analyzed for risk of Actinomyces-associated MRONJ...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27530108/therapeutic-interactions-between-mesenchymal-stem-cells-for-healing-medication-related-osteonecrosis-of-the-jaw
#19
Yuri Matsuura, Ikiru Atsuta, Yasunori Ayukawa, Takayoshi Yamaza, Ryosuke Kondo, Akira Takahashi, Nobuyuki Ueda, Wakana Oshiro, Yoshihiro Tsukiyama, Kiyoshi Koyano
BACKGROUND: Mesenchymal stem cells (MSCs) have been isolated from a variety of tissues, including bone marrow, adipose, and mucosa. MSCs have the capacity for self-renewal and differentiation. Reports have been published on the systemic administration of MSCs leading to functional improvements by engraftment and differentiation, thus providing a new strategy to regenerate damaged tissues. Recently, it has become clear that MSCs possess immunomodulatory properties and can therefore be used to treat diseases...
August 17, 2016: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/27501591/osteonecrosis-of-the-jaw-in-patients-receiving-bone-targeted-therapies-an-overview-part-i
#20
REVIEW
Bruce Turner, Lawrence Drudge-Coates, Sacha Ali, Jhumur Pati, Vinod Nargund, Enamul Ali, Leo Cheng, Paula Wells
Urologic patients receiving bone-targeted therapies are at risk of developing osteonecrosis of the jaw (ONJ). ONJ has historically been associated with bisphosphonate therapy. More recently, RANK-Ligand inhibitors (denosumab) have also been used to reduce the risk of skeletal-related events in patients who have advanced cancers with bone metastases. More than 65% of men with metastatic prostate cancer and nearly 75% of women with metastatic breast cancer are affected by bone metastases. The literature has described ONJ associated with bisphosphonate therapy as bisphosphonate-related osteonecrosis of the jaw (BRONJ)...
May 2016: Urologic Nursing
keyword
keyword
41952
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"